Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Open access
Sparano, Joseph A., Gray, Robert J., Makower, Della F., Albain, Kathy S., Saphner, Thomas J., Badve, Sunil S, Wagner, Lynne I., Kaklamani, Virginia G., Keane, Maccon M., Gomez, Henry L., Reddy, Pavan S., Goggins, Timothy F., Mayer, Ingrid A., Toppmeyer, Deborah L., Brufsky, Adam M., Goetz, Matthew P., Berenberg, Jeffrey L., Mahalcioiu, Catalin, Desbiens, Christine, Hayes, Daniel F., Dees, Elizabeth C., Geyer, Charles E., Olson, John A., Wood, William C, Lively, Tracy, Paik, Soonmyung, Ellis, Matthew J., Abrams, Jeffrey, Sledge, George W. · 2020 · JAMA Oncology

Abstract

Importance: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. Objective: To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endocrine therapy in the TAILORx trial, a population expected to have a high distant recurrence rate with endocrine therapy alone. Design, Setting, and Participants: In this secondary analysis of data from a multicenter randomized clinical trial, 1389 women with hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer, and a high RS of 26 to 100 were prospectively assigned to receive adjuvant chemotherapy in addition to endocrine therapy. The analysis was conducted on May 12, 2019. Interventions: The adjuvant chemotherapy regimen was selected by the treating physician. Main Outcomes and Measures: Freedom from recurrence of breast cancer at a distant site, and freedom from recurrence, second primary cancer, and death (also known as invasive disease-free survival [IDFS]). Results: Among the 9719 eligible women, with a mean age of 56 years (range 23-75 years), 1389 (14%) had a recurrence score of 26 to 100, of whom 598 (42%) had an RS of 26 to 30 and 791 (58%) had an RS of 31 to 100. The most common chemotherapy regimens included docetaxel/cyclophosphamide in 589 (42%), an anthracycline without a taxane in 334 (24%), an anthracycline and taxane in 244 (18%), cyclophosphamide/methotrexate/5-fluorouracil in 52 (4%), other regimens in 81 (6%), and no chemotherapy in 89 (6%). At 5 years, the estimated rate of freedom from recurrence of breast cancer at a distant site was 93.0% (standard error [SE], 0.8%), freedom of recurrence of breast cancer at a distant and/or local regional site 91.0% (SE, 0.8%), IDFS 87.6% (SE, 1.0%), and overall survival 95.9% (SE, 0.6%). Conclusions and Relevance: The estimated rate of freedom from recurrence of breast cancer at a distant site in women with an RS of 26 to 100 treated largely with taxane and/or anthracycline-containing adjuvant chemotherapy regimens plus endocrine therapy in the prospective TAILORx trial was 93% at 5 years, an outcome better than expected with endocrine therapy alone in this population. Trial Registration: ClinicalTrials.gov identifier: NCT00310180.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.4794

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 166

Metadata

Authors
Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F., Dees, E. C., Geyer, C. E., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J., & Sledge, G. W.
Venue
JAMA Oncology
Published
2020-03-01
Volume
6
Issue
3
Pages
367
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2977150399
Cited by
166
References
1
FWCI
5.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2019.4794
The paper
Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., . . . Sledge, G. W. (2020). Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.4794

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.